The estimated Net Worth of John Duncan Higgons is at least $11.8 Milhão dollars as of 15 April 2021. John Higgons owns over 200 units of Jounce Therapeutics Inc stock worth over $18,260 and over the last 11 years John sold JNCE stock worth over $11,816,558.
John has made over 43 trades of the Jounce Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently John sold 200 units of JNCE stock worth $2,000 on 15 April 2021.
The largest trade John's ever made was exercising 80,000 units of Jounce Therapeutics Inc stock on 19 March 2014 worth over $24,000. On average, John trades about 10,990 units every 52 days since 2014. As of 15 April 2021 John still owns at least 9,713 units of Jounce Therapeutics Inc stock.
You can see the complete history of John Higgons stock trades at the bottom of the page.
John's mailing address filed with the SEC is 780 Memorial Dr, Cambridge, MA 02139, USA.
Over the last 8 years, insiders at Jounce Therapeutics Inc have traded over $39,574,093 worth of Jounce Therapeutics Inc stock and bought 724,587 units worth $10,288,083 . The most active insiders traders include Kevin Ctang Capital Managem..., Harbor Master Investors (Ca..., eRock Ventures Ii, L.P.Third.... On average, Jounce Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $171,610. The most recent stock trade was executed by Richard /Ca/ Murray on 4 April 2023, trading 39,228 units of JNCE stock currently worth $72,572.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
Jounce Therapeutics Inc executives and other stock owners filed with the SEC include: